- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03976752
Body Compartment Pharmacokinetics of Anti-retroviral Agents That May be Considered for Future On-demand Peri-exposure HIV Prophylaxis Regimens
Study Overview
Detailed Description
Men who have sex with men (MSM) continue to be disproportionately affected by HIV. The majority of MSM acquire HIV after exposure to the rectal mucosa through unprotected receptive anal intercourse. Post-exposure-prophylaxis (PEP) is an intervention that is used to prevent HIV infection soon (72 hours) after a potential exposure. HIV-negative people with a possible exposure to HIV are instructed to take 28 days of a combination anti-HIV medication regimen, Truvada® + Raltegravir.
This study is being conducted to determine if the uptake of another anti-HIV medication, called Genvoya®, at different time-frames, is different at several body sites, including mucosal tissues. This medication might be considered for on-demand PEP regimens in the future.
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
Georgia
-
Atlanta, Georgia, United States, 30322
- Hope Clinic
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- HIV-negative man who reports receptive anal sex with another man in the last 6 months
- Aged 18-49 years
- Not currently taking PrEP and no plans to initiate during study
- Not currently taking PEP
- Able to provide informed consent in English
- No plans for relocation in the next 3 months
- Willing to undergo peripheral blood, penile swabs, urine, and rectal biopsy sampling
- Willing to use study products as directed
- Willing to abstain from receptive anal intercourse 3 days prior to starting study product and for the duration of the study and for 7 days after any rectal biopsy procedure.
- Hepatitis B surface antigen (HBsAg) must be negative (screening lab test)
- Creatine clearance >60 ml/min
Exclusion Criteria:
- History of inflammatory bowel disease or other inflammatory, infiltrative, infectious or vascular condition involving the lower gastrointestinal tract that, in the judgment of the investigators, may be worsened by study procedures or may significantly distort the anatomy of the distal large bowel
- Currently infected with hepatitis virus and/ or have liver disease
- Current or chronic history of kidney disease
Significant laboratory abnormalities at baseline visit, including but not limited to:
- Hgb ≤ 10 g/dL
- Partial thromboplastin time (PTT) > 1.5x upper limit of normal (ULN) or international normalized ratio (INR) > 1.5x ULN
- Platelet count <100,000
- Creatinine clearance <60
- HBsAg reactive
Any known medical condition that, in the judgment of the investigators, increases the risk of local or systemic complications of endoscopic procedures or pelvic examination, including but not limited to:
- Uncontrolled or severe cardiac arrhythmia
- Recent major abdominal, cardiothoracic, or neurological surgery
- History of uncontrolled bleeding diathesis
- History of colonic, rectal, or vaginal perforation, fistula, or malignancy
- History or evidence on clinical examination of ulcerative, suppurative, or proliferative lesions of the anorectal mucosa, or untreated sexually transmitted disease with mucosal involvement
Continued need for, or use during the 14 days prior to enrollment, of the following medications:
- Aspirin or more than 4 doses of NSAIDs
- Warfarin, heparin (low-molecular weight or unfractionated), platelet aggregation inhibitors, or fibrinolytic agents
- Any form of rectally administered agent besides lubricants or douching used for sexual intercourse
Continued need for, or use during the 90 days prior to enrollment, of the following medications:
- Systemic immunomodulatory agents
- Supraphysiologic doses of steroids (short course steroids less than 7 days duration, allowable at the discretion of the investigators)
- Experimental medications, vaccines, or biologicals
- Intent to use HIV antiretroviral pre/post-exposure prophylaxis (PrEP or PEP) during the study, outside of the study procedures
- Symptoms of an untreated rectal sexually transmitted infection (e.g. rectal pain, discharge, bleeding, etc.)
- Current use of hormonal therapy
- Any other clinical condition or prior therapy that, in the opinion of the investigator, would make the patient unsuitable for the study or unable to comply with the study requirements.
- Participants taking potent inhibitors (e.g. itraconazole, diltiazem) or inducers (e.g. rifampin, phenytoin) of the CYP3A4 enzyme that also metabolizes Genvoya will be excluded from the study
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Non-Randomized
- Interventional Model: Sequential Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
No Intervention: Pre-drug
Participants enrolled in the pre-drug arm will not receive any drug.
At visit 2, they will undergo blood, urine, penile swab, cheek swab, rectal swab and rectal biopsy collection.
|
|
Experimental: Genvoya - 2 and 48 hours specimen collection
Specimen collection 2 hours after taking the medication in the clinic (visit 4), and 48 hours after taking the medication in the clinic (visit 5).
|
Genvoya is a fixed-dose combination anti-retroviral drug containing tenofovir alafenamide (TAF), emtricitabine (FTC), elvitegravir (EVG), and cobicistat. At the second study visit, participants will be provided with a single dose of Genvoya, and instructed to take the dose at home with documentation by digital, time-stamped photo or video. At the third study visit, which will occur 24 hours after home dosing, participants will be given another single dose of Genvoya at the clinic.
Other Names:
|
Experimental: Genvoya - 4 and 72 hours specimen collection
Specimen collection 4 hours after taking the medication in the clinic (visit 4), and 72 hours after taking the medication in the clinic (visit 5).
|
Genvoya is a fixed-dose combination anti-retroviral drug containing tenofovir alafenamide (TAF), emtricitabine (FTC), elvitegravir (EVG), and cobicistat. At the second study visit, participants will be provided with a single dose of Genvoya, and instructed to take the dose at home with documentation by digital, time-stamped photo or video. At the third study visit, which will occur 24 hours after home dosing, participants will be given another single dose of Genvoya at the clinic.
Other Names:
|
Experimental: Genvoya - 24 and 96 hours specimen collection
Specimen collection 24 hours after taking the medication in the clinic (visit 4), and 96 hours after taking the medication in the clinic (visit 5).
|
Genvoya is a fixed-dose combination anti-retroviral drug containing tenofovir alafenamide (TAF), emtricitabine (FTC), elvitegravir (EVG), and cobicistat. At the second study visit, participants will be provided with a single dose of Genvoya, and instructed to take the dose at home with documentation by digital, time-stamped photo or video. At the third study visit, which will occur 24 hours after home dosing, participants will be given another single dose of Genvoya at the clinic.
Other Names:
|
Experimental: Genvoya - Single time point specimen collection
Specimen collection 8 hours after taking the medication in the clinic (visit 4).
|
Genvoya is a fixed-dose combination anti-retroviral drug containing tenofovir alafenamide (TAF), emtricitabine (FTC), elvitegravir (EVG), and cobicistat. At the second study visit, participants will be provided with a single dose of Genvoya, and instructed to take the dose at home with documentation by digital, time-stamped photo or video. At the third study visit, which will occur 24 hours after home dosing, participants will be given another single dose of Genvoya at the clinic.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Plasma Concentration of Tenofovir (TFV)
Time Frame: Baseline, and 2, 4, 8, 24, 48, 72, 96 hours after taking the second dose of medication
|
Median drug concentrations of the TFV component of Genvoya were determined at baseline and at each of the protocol specified follow-up time points.
Concentrations below the limit of quantification (LOQ) are assigned a value of zero.
|
Baseline, and 2, 4, 8, 24, 48, 72, 96 hours after taking the second dose of medication
|
Plasma Concentration of Emtricitabine (FTC)
Time Frame: Baseline, and 2, 4, 8, 24, 48, 72, 96 hours after taking the second dose of medication
|
Median drug concentrations of the FTC component of Genvoya were determined at baseline and at each of the protocol specified follow-up time points.
Concentrations below the limit of quantification (LOQ) are assigned a value of zero.
|
Baseline, and 2, 4, 8, 24, 48, 72, 96 hours after taking the second dose of medication
|
Plasma Concentration of Elvitegravir (EVG)
Time Frame: Baseline, and 2, 4, 8, 24, 48, 72, 96 hours after taking the second dose of medication
|
Median drug concentrations of the EVG component of Genvoya were determined at baseline and at each of the protocol specified follow-up time points.
Concentrations below the limit of quantification (LOQ) are assigned a value of zero.
|
Baseline, and 2, 4, 8, 24, 48, 72, 96 hours after taking the second dose of medication
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Peripheral Blood Mononuclear Cell (PBMC) Concentration of Tenofovir-diphosphate (TFV-DP)
Time Frame: Baseline, and 2, 4, 8, 24, 48, 72, 96 hours after taking the second dose of medication
|
A peripheral blood mononuclear cell (PBMC) is any peripheral blood cell having a round nucleus: lymphocytes (T cells, B cells, natural killer (NK) cells) and monocytes.
Median drug concentrations were determined at baseline and at each of the protocol specified follow-up time points.
Concentrations below the limit of quantification (LOQ) are assigned a value of zero.
|
Baseline, and 2, 4, 8, 24, 48, 72, 96 hours after taking the second dose of medication
|
Peripheral Blood Mononuclear Cell (PBMC) Concentration of Emtricitabine-triphosphate (FTC-TP)
Time Frame: Baseline, and 2, 4, 8, 24, 48, 72, 96 hours after taking the second dose of medication
|
A peripheral blood mononuclear cell (PBMC) is any peripheral blood cell having a round nucleus: lymphocytes (T cells, B cells, NK cells) and monocytes.
Median drug levels were determined at baseline and at each of the protocol specified follow-up time points.
Concentrations below the limit of quantification (LOQ) are assigned a value of zero.
|
Baseline, and 2, 4, 8, 24, 48, 72, 96 hours after taking the second dose of medication
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Rectal Tissue Concentration of Tenofovir (TFN)
Time Frame: Baseline, and 2, 4, 8, 24, 48, 72, 96 hours after taking the second dose of medication
|
Median drug concentrations in rectal tissue of the TFN component of Genvoya were determined at baseline and at each of the protocol specified time points.
Concentrations below the limit of quantification (LOQ) are assigned a value of zero.
|
Baseline, and 2, 4, 8, 24, 48, 72, 96 hours after taking the second dose of medication
|
Rectal Tissue Concentration of Emtricitabine (FTC)
Time Frame: Baseline, and 2, 4, 8, 24, 48, 72, 96 hours after taking the second dose of medication
|
Median drug concentrations in rectal tissue of the FTC component of Genvoya were determined at baseline and at each of the protocol specified time points.
Concentrations below the limit of quantification (LOQ) are assigned a value of zero.
|
Baseline, and 2, 4, 8, 24, 48, 72, 96 hours after taking the second dose of medication
|
Rectal Tissue Concentration of Elvitegravir (EVG)
Time Frame: Baseline, and 2, 4, 8, 24, 72, 96 hours after taking the second dose of medication
|
Median drug concentrations in rectal tissue of the EVG component of Genvoya were determined at baseline and at each of the protocol specified time points.
Concentrations below the limit of quantification (LOQ) are assigned a value of zero.
|
Baseline, and 2, 4, 8, 24, 72, 96 hours after taking the second dose of medication
|
Rectal Tissue Concentration of Tenofovir-diphosphate (TFV-DP)
Time Frame: Baseline, and 2, 4, 8, 24, 48, 72, 96 hours after taking the second dose of medication
|
Median drug concentrations of TFV-DP in rectal tissue were determined at baseline and at each of the protocol specified follow-up time points.
Concentrations below the limit of quantification (LOQ) are assigned a value of zero.
|
Baseline, and 2, 4, 8, 24, 48, 72, 96 hours after taking the second dose of medication
|
Rectal Tissue Concentration of Emtricitabine-triphosphate (FTC-TP)
Time Frame: Baseline, and 2, 4, 8, 24, 48, 72, 96 hours after taking the second dose of medication
|
Median drug concentrations of FTC-TP in rectal tissue were determined at baseline and at each of the protocol specified follow-up time points.
Concentrations below the limit of quantification (LOQ) are assigned a value of zero.
|
Baseline, and 2, 4, 8, 24, 48, 72, 96 hours after taking the second dose of medication
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Colleen Kelley, MD, Emory University
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- RNA Virus Infections
- Virus Diseases
- Infections
- Blood-Borne Infections
- Communicable Diseases
- Sexually Transmitted Diseases, Viral
- Sexually Transmitted Diseases
- Lentivirus Infections
- Retroviridae Infections
- Immunologic Deficiency Syndromes
- Immune System Diseases
- Slow Virus Diseases
- HIV Infections
- Acquired Immunodeficiency Syndrome
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Antiviral Agents
- Reverse Transcriptase Inhibitors
- Nucleic Acid Synthesis Inhibitors
- Enzyme Inhibitors
- Anti-HIV Agents
- Anti-Retroviral Agents
- Cytochrome P-450 CYP3A Inhibitors
- Cytochrome P-450 Enzyme Inhibitors
- Integrase Inhibitors
- Tenofovir
- Emtricitabine
- Emtricitabine tenofovir alafenamide
- Cobicistat
- Elvitegravir, Cobicistat, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination
- Elvitegravir
Other Study ID Numbers
- IRB00108386
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Time Frame
IPD Sharing Access Criteria
IPD Sharing Supporting Information Type
- Study Protocol
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on HIV/AIDS
-
University of MinnesotaWithdrawnHIV Infections | HIV/AIDS | Hiv | AIDS | Aids/Hiv Problem | AIDS and InfectionsUnited States
-
University of California, San DiegoNational Institute of Allergy and Infectious Diseases (NIAID)Completed
-
University of Massachusetts, BostonCompleted
-
Stanford UniversityJanssen Services, LLCCompleted
-
ViiV HealthcareJohns Hopkins University; Pfizer; Vanderbilt University; University of North Carolina...Completed
-
Medical College of WisconsinCompleted
-
Emory UniversityCompleted
-
Rhode Island HospitalUnknown
-
Tibotec Pharmaceuticals, IrelandCompleted
-
Lampiris, Harry W., M.D.AbbottUnknown
Clinical Trials on Genvoya
-
University of California, Los AngelesTulane University; Los Angeles LGBT CenterActive, not recruitingHuman Immunodeficiency VirusUnited States
-
Fundacion SEIMC-GESIDAMerck Sharp & Dohme LLCCompleted
-
Groupe d'Etude sur le Risque d'Exposition des Soignants...Gilead SciencesCompleted
-
Gilead SciencesCompletedHIV Infections | HIVUnited States, Netherlands, Spain, Mexico, France, Thailand, Australia, United Kingdom, Dominican Republic
-
Gilead SciencesCompletedHIV-1 InfectionSpain, France, United States, Germany, Italy
-
Henry M. Jackson Foundation for the Advancement...Gilead SciencesWithdrawn
-
Gilead SciencesCompletedHIVUnited States, South Africa
-
Gilead SciencesCompletedHIV | HBVUnited States, Canada, Japan
-
Gilead SciencesActive, not recruitingHIV Infections | Acquired Immune Deficiency Syndrome (AIDS)United States, Thailand, Uganda, South Africa, Zimbabwe
-
Gilead SciencesCompletedHIV Infections | Acquired Immunodeficiency Syndrome | HIV-1United States, Canada